On Jan. 06, Flynn James E divested U.S. $3,425,623 in shares of Lumos Pharma Inc.. The *Possible Member of 10% Group, 10% sold 151,723 shares at a price per share of $22.58. The transaction decreased this specific insider’s holdings to 784,568 shares worth around $17.39 million at present.
Cantor Fitzgerald launched its Lumos Pharma Inc. [LUMO] rating to the equivalent of a Buy and assigned the price target of $32, in a research note dated December 03, 2020. That figure represents around a 30.75% premium from where the company’s shares closed on Friday. Some new analysts also started their coverage, with Cantor Fitzgerald’s analysts assigning the shares to “a Buy” rating in a research note to investors issued in early December. Meanwhile, Piper Sandler had launched its coverage on LUMO with “an Overweight”, in a research note produced for clients August 26, 2020.
Is Lumos Pharma Inc. [NASDAQ:LUMO] a Good Buy Right Now?
It should be noted that LUMO technical indicators for short, intermediate as well as long term progress have placed an overall average of 80% as Buy. The average signal changed from 100% Buy in the last week and compares with 100% Buy in the past month. Data from Lumos Pharma Inc.’s Trend Spotter indicated that the signals were Falling. The stock current average is 67100.0 shares in the past 20 days and the short term average signal indicates a 50% Buy. In the last 50 days, the average trading volume was 32644.0 shares while the medium term average advocated for 100% Buy. The average long-term signal stands at 100% Buy and the 100-day average volume stands at 23641.0 shares.
LUMO Price Performance
On Wall Street, Lumos Pharma Inc. [NASDAQ:LUMO] finished Friday’s session down -6.34% at $22.16. The stock went up to $24.5741 at the same session while its lowest single day price was $22.04. In the last five days, it saw a fall of about -37.94%, Lumos Pharma Inc. shares dropped by almost -37.94% since the beginning of the year. However, the share price has dropped to as low as -39.65% below its one year high. On 01/04/21, the company shares recorded $35.45, the highest single-day price it has got to in the last 52-weeks and a 52-week low was seen on 01/06/21, the same year at $20.23. The company’s shares have inclined by 12.43% in the past year. The 50-day SMA achieved is $19.15 while the 200-day SMA is $14.83. Volume gained to 0.13 million from 61900.0 in the previous session.
LUMO Stock Support And Resistance Levels
On the 24-hour scale, the immediate backing is perceived around 21.28 level, and in case of violation of this particular level, it will cause more drop to 20.39 level. On the upper level, 25.46 is still the key resistance. The stock may increase to the subsequent resistance at 23.81. The Relative Strength Index (RSI) pinned on the 14-day chart is 47.15, implying a neutral technical stance while the MACD stands at -4.99, meaning price will decrease in the next trading period. Percent R indicator moved to 88.30%, implying bearish price movement. Stochastic %K at 16.78% suggest buying the stock.
What is the short interest in Lumos Pharma Inc.?
Short interest in the Lumos Pharma Inc. stock has plunged, decreasing by 8520.0 shares to total 0.19 million shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 0.18 million, data from Yahoo Finance shows. The increase of 4.48% suggests the stock saw some increased bearish sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account for just 3.56% of the overall float for the stock.
Lumos Pharma Inc.’s Biggest Shareholders: Who Owns Lumos Pharma Inc. [LUMO]?
Filings by Deerfield Management Company LP showed that the firm now holds a total of 936,291 shares or roughly 11.29% of the outstanding LUMO shares. This means their shares have increased by 122 from the 936,291 the investor reportedly held in its prior 13-F filing. With the conclusion of the purchase, Lion Point Capital LP updated stake is worth $6,144,527. Details in the latest 13F filings reveal that Renaissance Technologies LLC disposed off their -1.00% stake valued at $4,619,230. During the last quarter, Renaissance Technologies LLC liquidated -3,079 of its shares in Lumos Pharma Inc. while Opaleye Management, Inc. bought 240,892 shares. The The Vanguard Group, Inc.’s holdings currently number 220,838 shares at $4893770.08. According to the firm’s last 13F report, Leucadia Asset Management LLC shares in the company at filing stood at 120,651 shares, roughly $1,820,624.
LUMO Earnings Forecast For The Current Quarter
Lumos Pharma Inc. [LUMO] is expected to report strong earnings results for the quarter ending on Dec 2020. Consensus estimates give the company expected revenues of $10k and an earnings per share of -$0.86 for Dec 2020.
LUMO Earnings Estimates For The Current Year
For the financial year, Lumos Pharma Inc. [NASDAQ:LUMO] is expected to bring in revenue of $140k. The returns are nearly $-0.8 million lower than the company’s actual revenue recorded in the fiscal year 2019. In terms of EPS for the 2020, estimate put it at -1.5, higher than that of FY19 by $8.85. Estimates put this year’s earnings growth at 85.50%, -152.70% for the next, and at an annual 15.20% over the next 5-year period. As for sales, forecasts are for a decrease of -85.00% in the current fiscal year.
What are analyst thoughts on Lumos Pharma Inc.?
Looking forward to the Lumos Pharma Inc. share price prediction, we can see that analysts, surveyed by FactSet, offer the mean price target for Lumos Pharma Inc. stock at $32.00 within the next 12 months, which represents almost 30.75 per cent growth from its previous closing price of $22.16. The highest analysts’ target for Lumos Pharma Inc. stock projections is $51.00 and the lowest one is $22.00. Still, 5 analysts sharing their consensus rating for LUMO stock in 2021 agree that it is a Buy.